NeuroBo signs joint research agreement for once-monthly obesity therapy DA-1726

MetaVia Inc.

Collaboration with Dong-A ST and ImmunoForge to develop long-acting formulation of GLP1R/GCGR dual agonist DA-1726.
ImmunoForge's ELP platform can extend drug half-life up to 200x, enabling once-monthly injection.
DA-1726 currently in Phase 1; financial terms of the agreement not disclosed.
Goal is to improve patient compliance and ease of administration for obesity treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.